2019冠状病毒病(COVID-19)患者出凝血功能障碍的研究进展  

Coagulation dysfunction in COVID-19

作　　者：徐亦鸣 吕丹丹 应可净[1] XU Yiming;LYU Dandan;YING Kejing(Department of Respiratory Medicine,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou 310016,China)

机构地区：[1]浙江大学医学院附属邵逸夫医院呼吸内科,浙江杭州310016

出　　处：《浙江大学学报（医学版）》2020年第3期340-346,共7页Journal of Zhejiang University(Medical Sciences)

基　　金：国家自然科学基金(81970049)。

摘　　要：2019冠状病毒病(COVID-19)患者除常见临床特征之外,还有不同程度的出凝血功能障碍,存在合并血栓和/或出血的风险。COVID-19相关的出凝血功能障碍多为动态过程,可伴有弥散性血管内凝血的形成,与疾病危重程度相关。严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染后所导致的机体免疫炎症反应失衡是患者凝血功能紊乱的重要原因,动态监测、早期防治对于改善患者预后有重大意义。本文就COVID-19患者出凝血功能障碍相关研究进展作一综述,以期为临床研究及决策提供参考。In addition to common clinical features,patients with coronavirus disease 2019(COVID-19)have varying degree of coagulation dysfunction with the risk of thrombosis and/or bleeding.COVID-19 related coagulation dysfunction is a dynamic process,which may be accompanied by the formation of disseminated intravascular coagulation and is related to the severity of the disease.The imbalance of the body s immune and inflammatory response caused by coronavirus infection is an important cause of coagulation dysfunction.Dynamic monitoring as well as early prevention and treatment are of great significance for improving the prognosis of patients.This article reviews the research progress of COVID-19 related coagulation dysfunction,to provide reference for clinical research and management.

关 键 词：2019冠状病毒病 严重急性呼吸综合征冠状病毒2 新型冠状病毒肺炎 出凝血功能障碍 炎症 免疫 

分 类 号：R512.99[医药卫生—内科学]